Blenrep
| Chemical Name | belantamab mafodotin |
| Dosage Form | Injection; (Iintravenous; 100mg) |
| Drug Class | Antineoplastics |
| System | Blood |
| Company | GlaxoSmithKline plc |
| Approval Year | 2020 |
Indication
- For the treatment of adult patients with relapsed or refractory multiple myeloma who have received at least 4 prior therapies including an anti-CD38 monoclonal antibody, a proteasome inhibitor, and an immunomodulatory agent.